Stocktoria
Celldex Therapeutics, Inc. CLDX
Celldex Therapeutics, Inc. (CLDX) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $1.5M at a -16748.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-15 | HC Wainwright & Co. | Buy (reit) |
| 2026-06-10 | UBS | Buy (main) |
| 2026-05-13 | Wells Fargo | Overweight (main) |
| 2026-05-08 | Barclays | Overweight (main) |
| 2026-04-20 | Barclays | Overweight (up) |
| 2026-03-02 | Goldman Sachs | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.83 |
| Retained earnings / assets | -3.112 |
| EBIT / assets | -0.493 |
| Equity / liabilities | 9.444 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CLDX | Celldex Therapeutics, Inc. | 1/9 | 1.9 | — | — |
| CDIO | Cardio Diagnostics Holdings, Inc. | 1/9 | -4.17 | — | — |
| IMDX | Insight Molecular Diagnostics Inc. | 3/9 | — | — | — |
| BMRA | BIOMERICA INC | 2/9 | — | — | — |
| NNNN | Anbio Biotechnology | 4/9 | — | 326.5 | — |
| ICCC | IMMUCELL CORP /DE/ | 6/9 | 2.93 | — | +4.3% |
| TKNO | Alpha Teknova, Inc. | 5/9 | -1.59 | — | +7.4% |
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
FAQ
Is CLDX financially healthy?
Celldex Therapeutics, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does CLDX pay a dividend?
No, Celldex Therapeutics, Inc. does not currently pay a dividend.
How profitable is CLDX?
In FY2025, Celldex Therapeutics, Inc. had a net margin of -16748.0% and a return on equity of -49.1%.
What is the analyst price target for CLDX?
The average Wall-Street price target for Celldex Therapeutics, Inc. is $57.53, about 28.2% above the recent price, from 15 analysts (consensus: strong buy).
Is CLDX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Celldex Therapeutics, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.